Nicolescu Alin Codruț, Strilciuc Stefan, Lăpădatu Rozalina, Grad Diana-Alecsandra, Vlădescu Cristian, Olteanu Rodica
Emergency Hospital Prof. Dr. Agrippa Ionescu, Bucharest, Romania.
Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Front Public Health. 2025 Jan 9;12:1531042. doi: 10.3389/fpubh.2024.1531042. eCollection 2024.
Atopic dermatitis (AD), a common dermatological condition, is often associated with significant economic and social burdens. Despite extensive studies globally, there is a gap in understanding the impact of this condition in Romania. This study evaluated the economic burden of AD in Romania, considering both direct and indirect costs.
A cost of illness study, conducted from a broad perspective, considering 2022 as a reference, using top-down and bottom-up approaches and retrospective and prospective data sources was used to assess direct medical costs (treatments, medical services, hospitalizations), direct non-medical costs (associated costs due to transportation, accommodation), and indirect costs (productivity losses) across four costing scenarios.
In 2022, the total cost of atopic dermatitis in Romania was €29,810,077.2 for adult patients and €133,635,535.2 for pediatric patients, based on a prevalence-based approach, and €5,529,867.8 for adults and €53,175,049.1 for pediatric AD patients when using an incidence-based approach. Medical costs had the highest attributable share of the AD cost for adult patients while productivity costs (inquired by caregivers) had the highest share for pediatric AD patients in both approaches. The overall average annual cost per patient ranged, depending on the scenarios, between €284.72 and €1,045 for adult AD patients and between €293.73 and €9,558.52 for pediatric AD patients.
Our results show the increased burden among pediatric AD patients emphasizing the need that future policy interventions should be tailored according the patients' age.
特应性皮炎(AD)是一种常见的皮肤病,常伴随着巨大的经济和社会负担。尽管全球范围内进行了广泛研究,但在了解这种疾病在罗马尼亚的影响方面仍存在差距。本研究评估了罗马尼亚特应性皮炎的经济负担,同时考虑了直接成本和间接成本。
采用疾病成本研究,从广泛的角度进行,以2022年为参考,使用自上而下和自下而上的方法以及回顾性和前瞻性数据源,评估了四种成本计算情景下的直接医疗成本(治疗、医疗服务、住院)、直接非医疗成本(交通、住宿相关成本)和间接成本(生产力损失)。
基于患病率的方法,2022年罗马尼亚成年特应性皮炎患者的总成本为29,810,077.2欧元,儿科患者为133,635,535.2欧元;采用发病率法时,成年患者为5,529,867.8欧元,儿科特应性皮炎患者为53,175,049.1欧元。在两种方法中,医疗成本在成年患者的特应性皮炎成本中所占归因份额最高,而生产力成本(由照顾者报告)在儿科特应性皮炎患者中所占份额最高。根据情景不同,成年特应性皮炎患者每位患者的总体平均年度成本在284.72欧元至1,045欧元之间,儿科特应性皮炎患者在293.73欧元至9,558.52欧元之间。
我们的结果显示儿科特应性皮炎患者的负担增加,强调未来政策干预应根据患者年龄进行调整这一需求。